Serum and Uterine Progesterone Levels and ERA Test.
Launched by INSTITUTO VALENCIANO DE INFERTILIDAD, IVI VALENCIA · Feb 28, 2018
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
In patients who have had problems of assisted reproduction it is essential to establish the factors that contribute to the success of a cycle: correcting these factors means increasing the possibility of the cycle culminating in pregnancy.
In patients with embryonic implantation failures, a prevalence of non-receptive endometrium has been described after performing the ERA test of around 20%. On the other hand, a study that shows embryonic generation values below a certain threshold (25th percentile), presents a rate of evolutionary clinical gestation and lower embryo implantation.
It is ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Infertile women \<50 years
- • One or more failed IVF treatments
- • Undergoing an artificial endometrial preparation cycle with hormonal replacement therapy in order to perform an endometrial receptivity analysis through ERA test.
- • Endometrial thickness after estrogen treatment \> 6.5 mm with trilaminar structure
- Exclusion Criteria:
- • Uterine alterations (fibroids, polyps or Müllerian abnormalities)
- • Adnexal pathology
About Instituto Valenciano De Infertilidad, Ivi Valencia
Instituto Valenciano de Infertilidad (IVI Valencia) is a leading fertility clinic and research institution dedicated to advancing reproductive health and assisted reproductive technologies. With a commitment to providing personalized care and innovative treatment options, IVI Valencia conducts clinical trials aimed at enhancing the understanding and effectiveness of infertility therapies. The institute combines state-of-the-art facilities with a team of experienced specialists, ensuring high standards of patient safety and ethical research practices. IVI Valencia plays a pivotal role in fostering scientific advancements in the field of reproductive medicine, ultimately striving to improve outcomes for individuals and couples facing fertility challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Trial Officials
Elena Labarta, MD
Principal Investigator
IVI Vakencia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials